JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX) announced today that Yuri Shoshan, Vice President of Finance and Corporate Development, will present a company overview and recently announced data from a phase 2a trial of BL-1020, a GABA-enhanced antipsychotic, at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008, at 10:15 AM ET at The Waldorf-Astoria Hotel in New York City.
